TScan Therapeutics, Inc.
TCRX
$0.97
$0.1315.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -124.31M | -129.77M | -142.60M | -136.78M | -131.48M |
| Total Depreciation and Amortization | 2.88M | 2.87M | 2.85M | 3.11M | 3.53M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.10M | 9.76M | 10.11M | 8.50M | 8.03M |
| Change in Net Operating Assets | -10.69M | -18.18M | -1.10M | -1.02M | 779.00K |
| Cash from Operations | -122.01M | -135.32M | -130.73M | -126.18M | -119.14M |
| Capital Expenditure | -2.95M | -4.41M | -5.12M | -5.07M | -4.65M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 98.72M | 113.78M | 126.96M | 11.98M | -70.59M |
| Cash from Investing | 95.77M | 109.37M | 121.84M | 6.91M | -75.25M |
| Total Debt Issued | -- | -- | 32.46M | 32.46M | 32.46M |
| Total Debt Repaid | -- | -- | -17.14M | -17.14M | -17.14M |
| Issuance of Common Stock | 264.00K | 264.00K | 569.00K | 1.80M | 34.92M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -75.00K | -600.00K | 29.40M | 29.40M | 157.75M |
| Cash from Financing | 189.00K | -336.00K | 45.28M | 46.51M | 207.98M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.05M | -26.28M | 36.39M | -72.77M | 13.60M |